TheraRadar
← Back
Data updated: Sep 20, 2026

REGCON HOLDINGS

Generics

REGCON HOLDINGS is a generic drug manufacturer focused on Cardiovascular, Neurology, Gastroenterology.

1999
Since
47
Drugs
-
Trials
1
New Drugs (2yr)
Modality:

REGCON HOLDINGS's Key Drugs

REGCON HOLDINGS's core commercial portfolio centers on BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

REGCON HOLDINGS's Therapeutic Areas

REGCON HOLDINGS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 33%
6 drugs
Neurology 28%
5 drugs
Gastroenterology 17%
3 drugs
Infectious Disease 11%
2 drugs
Ophthalmology 11%
2 drugs

REGCON HOLDINGS Pipeline Snapshot

Active clinical trials for REGCON HOLDINGS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • BRIMONIDINE TARTRATE AND TIMOLOL MALEATE leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling